Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition

BACKGROUND: In ALK-positive advanced NSCLC, crizotinib has a high response rate and effectively increases quality of life and survival. CT measurement of the tumor may insufficiently reflect the actual tumor load changes during targeted therapy with crizotinib. We explored whether (18)F-FDG PET meas...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:PLoS One
Main Authors: Kerner, Gerald S. M. A., Koole, Michel J. B., Bongaerts, Alphons H. H., Pruim, Jan, Groen, Harry J. M.
Formato: Artigo
Idioma:Inglês
Publicado: Public Library of Science 2016
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4854442/
https://ncbi.nlm.nih.gov/pubmed/27137772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0149955
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares